Oncology Diagnostics Global Markets Report 2025: Expanding Cancer Screening and Enhanced Access to Advanced Technologies Bolster Opportunities - Forecast to 2029
DUBLIN--(BUSINESS WIRE)--Jun 11, 2025--
The 'Oncology Diagnostics: Global Markets' report has been added to ResearchAndMarkets.com's offering.
The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.
The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.
This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.
The oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets.
Key Attributes:
The report includes:
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Oncology Diagnostics Market
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective
Chapter 9 Appendix
List of Tables
Summary Table: Global Market for Oncology Diagnostics, by Product Type, Through 2029
Table 1: Global Incidence of All Cancer Cases, by WHO Region, 2022-2045
Table 2: Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022
Table 3: Cancer Treatments Based on Specific Tests
Table 4: Select FDA-Approved AI-Associated/Associable-Equipped Medical Devices
Table 5: Selected Patent Grants in Oncology Diagnostics, 2023-2025
Table 6: Global Oncology Diagnostics Market, by Product Type, Through 2029
Table 7: Global Diagnostics Imaging Market, by Region, Through 2029
Table 8: Global Endoscopy Market, by Region, Through 2029
Table 9: Global Tumor Biomarker Tests Market, by Region, Through 2029
Table 10: Global Biopsy Devices Market, by Region, Through 2029
Table 11: Global H&E and Special Stains Diagnostics Market, by Region, Through 2029
Table 12: Global IHC Oncology Diagnostics Market, by Region, Through 2029
Table 13: Global ISH Oncology Diagnostics Market, by Region, Through 2029
Table 14: Global PCR Oncology Diagnostics Market, by Region, Through 2029
Table 15: Global NGS Oncology Diagnostics Market, by Region, Through 2029
Table 16: Global Other Oncology Diagnostics Tests Market, by Region, Through 2029
Table 17: Global Oncology Diagnostics Market, by Application, Through 2029
Table 18: Global Breast Cancer Diagnostics Market, by Region, Through 2029
Table 19: Global Lung Cancer Diagnostics Market, by Region, Through 2029
Table 20: Global Colorectal Cancer Diagnostics Market, by Region, Through 2029
Table 21: Global Prostate Cancer Diagnostics Market, by Region, Through 2029
Table 22: Global Gastric Cancer Diagnostics Market, by Region, Through 2029
Table 23: Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029
Table 24: Global Oncology Diagnostics Market, by End User, Through 2029
Table 25: Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029
Table 26: Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029
Table 27: Global Oncology Diagnostics Market in Other End Uses, Through 2029
Table 28: Global Oncology Diagnostics Market, by Region, Through 2029
Table 29: North American Oncology Diagnostics Market, by Country, Through 2029
Table 30: U.S. Oncology Diagnostics Market, by Product Type, Through 2029
Table 31: U.S. Oncology Diagnostics Market, by Application, Through 2029
Table 32: U.S. Oncology Diagnostics Market, by End User, Through 2029
Table 33: Canadian Oncology Diagnostics Market, by Product Type, Through 2029
Table 34: Canadian Oncology Diagnostics Market, by Application, Through 2029
Table 35: Canadian Oncology Diagnostics Market, by End User, Through 2029
Table 36: Mexican Oncology Diagnostics Market, by Product Type, Through 2029
Table 37: Mexican Oncology Diagnostics Market, by Application, Through 2029
Table 38: Mexican Oncology Diagnostics Market, by End User, Through 2029
Table 39: European Oncology Diagnostics Market, by Country, Through 2029
Table 40: Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022
Table 41: German Oncology Diagnostics Market, by Product Type, Through 2029
Table 42: German Oncology Diagnostics Market, by Application, Through 2029
Table 43: German Oncology Diagnostics Market, by End User, Through 2029
Table 44: Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022
Table 45: French Oncology Diagnostics Market, by Product Type, Through 2029
Table 46: French Oncology Diagnostics Market, by Application, Through 2029
Table 47: French Oncology Diagnostics Market, by End User, Through 2029
Table 48: New Cases of Cancer Diagnosed Each Year in the U.K., 2021
Table 49: The U.K. Oncology Diagnostics Market, by Product Type, Through 2029
Table 50: The U.K. Oncology Diagnostics Market, by Application, Through 2029
Table 51: The U.K. Oncology Diagnostics Market, by End User, Through 2029
Table 52: Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022
Table 53: Italian Oncology Diagnostics Market, by Product Type, Through 2029
Table 54: Italian Oncology Diagnostics Market, by Application, Through 2029
Table 55: Italian Oncology Diagnostics Market, by End User, Through 2029
Table 56: Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022
Table 57: Spanish Oncology Diagnostics Market, by Product Type, Through 2029
Table 58: Spanish Oncology Diagnostics Market, by Application, Through 2029
Table 59: Spanish Oncology Diagnostics Market, by End User, Through 2029
Table 60: Rest of European Countries' Oncology Diagnostics Market, by Product Type, Through 2029
Table 61: Rest of European Countries' Oncology Diagnostics Market, by Application, Through 2029
Table 62: Rest of European Countries' Oncology Diagnostics Market, by End User, Through 2029
Table 63: Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029
Table 64: Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022
Table 65: Chinese Oncology Diagnostics Market, by Product Type, Through 2029
Table 66: Chinese Oncology Diagnostics Market, by Application, Through 2029
Table 67: Chinese Oncology Diagnostics Market, by End User, Through 2029
Table 68: Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022
Table 69: Japanese Oncology Diagnostics Market, by Product Type, Through 2029
Table 70: Japanese Oncology Diagnostics Market, by Application, Through 2029
Table 71: Japanese Oncology Diagnostics Market, by End User, Through 2029
Table 72: Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022
Table 73: Indian Oncology Diagnostics Market, by Product Type, Through 2029
Table 74: Indian Oncology Diagnostics Market, by Application, Through 2029
Table 75: Indian Oncology Diagnostics Market, by End User, Through 2029
Table 76: Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029
Table 77: Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029
Table 78: Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029
Table 79: South American Oncology Diagnostics Market, by Country, Through 2029
Table 80: Brazilian Oncology Diagnostics Market, by Product Type, Through 2029
Table 81: Brazilian Oncology Diagnostics Market, by Application, Through 2029
Table 82: Brazilian Oncology Diagnostics Market, by End User, Through 2029
Table 83: Argentine Oncology Diagnostics Market, by Product Type, Through 2029
Table 84: Argentine Oncology Diagnostics Market, by Application, Through 2029
Table 85: Argentine Oncology Diagnostics Market, by End User, Through 2029
Table 86: Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029
Table 87: Rest of South American Oncology Diagnostics Market, by Application, Through 2029
Table 88: Rest of South American Oncology Diagnostics Market, by End User, Through 2029
Table 89: Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029
Table 90: Middle East and African Oncology Diagnostics Market, by Application, Through 2029
Table 91: Middle East and African Oncology Diagnostics Market, by End User, Through 2029
Table 92: Company Shares in the Oncology Diagnostics Market, 2023
Table 93: ESG: Environmental Overview
Table 94: ESG: Social Overview
Table 95: ESG: Governance Overview
Table 96: Abbreviations Used in this Report
Table 97: Abbott: Company Snapshot
Table 98: Abbott: Financial Performance, FY 2022 and 2023
Table 99: Abbott: Product Portfolio
Table 100: Agilent Technologies Inc.: Company Snapshot
Table 101: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 102: Agilent Technologies Inc.: Product Portfolio
Table 103: Agilent Technologies Inc.: News/Key Developments, 2024
Table 104: BD: Company Snapshot
Table 105: BD: Financial Performance, FY 2023 and 2024
Table 106: BD: Product Portfolio
Table 107: bioMerieux: Company Snapshot
Table 108: bioMerieux: Financial Performance, FY 2022 and 2023
Table 109: bioMerieux: Product Portfolio
Table 110: Bio-Rad Laboratories Inc.: Company Snapshot
Table 111: Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 112: Bio-Rad Laboratories Inc.: Product Portfolio
Table 113: Danaher Corp.: Company Snapshot
Table 114: Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 115: Danaher Corp.: Product Portfolio
Table 116: Danaher Corp.: News/Key Developments, 2023
Table 117: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 118: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 119: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 120: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025
Table 121: GE HealthCare: Company Snapshot
Table 122: GE HealthCare: Financial Performance, FY 2023 and 2024
Table 123: GE HealthCare: Product Portfolio
Table 124: GE HealthCare: News/Key Developments, 2024
Table 125: Illumina Inc.: Company Snapshot
Table 126: Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 127: Illumina Inc.: Product Portfolio
Table 128: Illumina Inc.: News/Key Developments, 2024
Table 129: Koninklijke Philips N.V.: Company Snapshot
Table 130: Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024
Table 131: Koninklijke Philips N.V.: Product Portfolio
Table 132: Merck KGaA: Company Snapshot
Table 133: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 134: Merck KGaA: Product Portfolio
Table 135: Myriad Genetics Inc.: Company Snapshot
Table 136: Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
Table 137: Myriad Genetics Inc.: Product Portfolio
Table 138: Myriad Genetics Inc.: News/Key Developments, 2025
Table 139: Qiagen: Company Snapshot
Table 140: Qiagen: Financial Performance, FY 2022 and 2023
Table 141: Qiagen: Product Portfolio
Table 142: Siemens Healthineers AG: Company Snapshot
Table 143: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 144: Siemens Healthineers AG: Product Portfolio
Table 145: Siemens Healthineers AG: News/Key Developments, 2024
Table 146: Thermo Fisher Scientific Inc.: Company Snapshot
Table 147: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 148: Thermo Fisher Scientific Inc.: Product Portfolio
Table 149: Thermo Fisher Scientific Inc.: News/Key Developments, 2023
Table 150: ZytoVision GmbH: Company Snapshot
Table 151: ZytoVision GmbH: Product Portfolio
Table 152: Emerging Startups in Oncology Diagnostics Market
List of Figures
Summary Figure: Global Market Shares of Oncology Diagnostics, by Product Type, 2023
Figure 1: Porter's Five Forces Analysis of the Oncology Market
Figure 2: Market Dynamics of Oncology Diagnostics
Figure 3: Global Incidence Shares of All Cancer Cases, by Region, 2022
Figure 4: Number of FDA-Approved Companion Diagnostic Devices, 1997-2024
Figure 5: Emerging Trends and Technologies in Oncology Diagnostics
Figure 6: Share of Global Market for Oncology Diagnostics, by Product Type, 2023
Figure 7: Share of Global Market for Oncology Diagnostics, by Application, 2023
Figure 8: Shares of Global Market for Oncology Diagnostics, by End User, 2023
Figure 9: Share of Global Market for Oncology Diagnostics, by Region, 2023
Figure 10: Share of North American Market for Oncology Diagnostics, by Country, 2023
Figure 11: Share of European Market for Oncology Diagnostics, by Country, 2023
Figure 12: Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022
Figure 13: Cervical Cancer Screening Rates in European Countries, 2022
Figure 14: Colorectal Cancer Screening Rates in European Countries, 2022
Figure 15: Current and Forecasted Cancer Prevalence in the U.K., 2020-2040
Figure 16: Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022
Figure 17: Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022
Figure 18: Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023
Figure 19: Share of South American Market for Oncology Diagnostics, by Country, 2023
Figure 20: Share of the Global Market for Oncology Diagnostics, by Company, 2023
Figure 21: ESG Pillars
Figure 22: Advantages of ESG for Companies
Figure 23: Abbott: Revenue Share, by Business Unit, FY 2023
Figure 24: Abbott: Revenue Share, by Country/Region, FY 2023
Figure 25: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
Figure 26: Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
Figure 27: BD: Revenue Share, by Business Unit, FY 2024
Figure 28: BD: Revenue Share, by Country/Region, FY 2024
Figure 29: bioMerieux: Revenue Share, by Business Unit, FY 2023
Figure 30: bioMerieux: Revenue Share, by Region, FY 2023
Figure 31: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 32: Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 33: Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 34: Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 35: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 36: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 37: GE HealthCare: Revenue Share, by Business Unit, FY 2024
Figure 38: GE HealthCare: Revenue Share, by Country/Region, FY 2024
Figure 39: Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 40: Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 41: Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024
Figure 42: Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023
Figure 43: Merck KGaA: Market Share, by Business Unit, 2023
Figure 44: Merck KGaA: Revenue Share, by Country/Region, 2023
Figure 45: Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023
Figure 46: Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023
Figure 47: Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 48: Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 49: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 50: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 51: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 52: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/oz3l3k
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250611111288/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 06/11/2025 08:39 AM/DISC: 06/11/2025 08:37 AM
http://www.businesswire.com/news/home/20250611111288/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
DigitalOcean and AMD Collaborate to Advance AI Using Cloud-Based GPUs
NEW YORK--(BUSINESS WIRE)-- DigitalOcean Holdings, Inc. (NYSE: DOCN), the simplest scalable cloud for digital native enterprises, today announced a collaboration with AMD that provides DigitalOcean customers with access to AMD Instinct™ GPUs as DigitalOcean GPU Droplets to power their AI workloads starting with the AMD MI300X GPUs. Later this year, DigitalOcean will offer AMD Instinct™ MI325X GPUs, further expanding access to powerful and affordable GPU models. AMD Instinct™ MI325X GPU accelerators set new AI performance standards, delivering incredible performance and efficiency for training and inference. AMD Instinct MI300X GPUs deliver leadership performance for accelerated high-performance computing (HPC) applications and the newly exploding demands of generative AI. With the AMD ROCm™ software platform, customers can develop powerful HPC and AI production-ready systems faster than ever before. Its large memory capacity allows it to hold models with hundreds of billions of parameters entirely in memory, reducing the need for model splitting across multiple GPUs. By combining powerful AMD AI compute engines and DigitalOcean's cloud technologies, the collaboration aims to empower the massive community of digital native enterprises to integrate AI into their applications and support the most demanding AI workloads at scale. These next-generation GPUs have already been available in bare metal configurations for customers seeking increased control and computing power. These GPUs are now also available as GPU Droplets or as DigitalOcean Kubernetes worker nodes. The GPU Droplets are available both as single and eight GPU configurations, allowing customers to optimize costs for their specific use cases. Accessing these GPU Droplets through DigitalOcean offers several key benefits, including competitive pricing at $1.99/GPU per hour, a simple setup process, and enterprise-grade SLAs. While other cloud providers require multiple steps and deep technical knowledge to configure security, storage, and network requirements, DigitalOcean's GPU Droplets can be set up with just a few clicks. In addition to these new GPUs, customers will also have access to AMD Developer Cloud, a new platform powered by DigitalOcean that is purpose-built for rapid, high-performance AI development. Customers will have access to a fully managed environment that provides instant access to AMD Instinct MI300X GPUs—with zero hardware investment or local setup required. Whether fine-tuning LLMs, benchmarking inference performance, or building a scalable inference stack, the AMD Developer Cloud provides the tools and flexibility to get started instantly—and grow without limits. 'DigitalOcean's collaboration with AMD is another proof point to make AI easily accessible to our customers,' said Bratin Saha, Chief Product & Technology Officer at DigitalOcean. 'With access to AMD GPUs, DigitalOcean customers have an extensive portfolio of GPUs with the flexibility of the computing configuration that best suits their requirements.' "At AMD, we are proud to work with DigitalOcean to provide developers with cutting-edge solutions for developer enablement and demanding workloads that require large amounts of memory,' said Negin Oliver, corporate vice president of business development, Data Center GPU Business, at AMD. 'Together, AMD and DigitalOcean are committed to providing the critical innovative technologies required to support the evolving needs of growing tech businesses.' To access AMD Instinct GPUs with DigitalOcean, visit the DigitalOcean website. DigitalOcean is the simplest scalable cloud platform that democratizes cloud and AI for digital native enterprises around the world. Our mission is to simplify cloud computing and AI to allow builders to spend more time creating software that changes the world. More than 600,000 customers trust DigitalOcean to deliver the cloud, AI, and ML infrastructure they need to build and scale their organizations. To learn more about DigitalOcean, visit
Business Wire
an hour ago
- Business Wire
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' This report stated that Grizzly believed that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, GeneDx stock fell 6.7% on February 5, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time, Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
an hour ago
- Business Wire
InPlay Unveils 2nd-Gen NanoBeacon IN120 SoC: Unlocking Game-Changing Efficiency for Smart Label Makers with Integrated Temperature Sensor!
IRVINE, Calif.--(BUSINESS WIRE)--InPlay Inc., a leader in ultra-low-power wireless SoC technologies, announces the upcoming release of its revolutionary second-generation NanoBeacon System-on-Chip (SoC), the IN120. Specifically engineered for high-volume smart label applications, the IN120 delivers unprecedented simplicity, cost savings, and manufacturing efficiency. "By reducing external components to just one, we've enabled manufacturers to produce smart labels more efficiently and economically—opening the door to broader deployment in logistics, pharmaceuticals, and disposable asset tracking." Share The IN120 features an ultra-minimalist design, requiring only one external component—a 26MHz crystal. This design innovation dramatically reduces complexity, enabling significant savings in assembly time, manufacturing costs, and supply chain logistics. Delivered in a bumped wafer Known Good Die (KGD) format, the IN120 integrates effortlessly into existing roll-to-roll RFID inlay manufacturing processes, minimizing the need for new capital investments. A key highlight of the IN120 is its integrated precision temperature sensor (±1°C accuracy), eliminating the need for an external temperature sensing component typically required in cold chain monitoring and logistics applications. This integrated approach not only lowers component costs but also enhances reliability and simplifies production processes. "Our new IN120 SoC sets a benchmark for smart label technology," said Jason Wu, Cofounder and CEO of InPlay Inc. "By reducing external components to just one, we have enabled manufacturers to produce smart labels more efficiently and economically, opening the door to broader deployment in logistics, pharmaceuticals, and disposable asset tracking." Further elevating its practicality, the IN120 supports a broad voltage range from 1.1V to 3.6V, compatible with virtually all battery types, including cost-effective printable batteries (1.5V per cell). This flexibility significantly reduces the cost and footprint of smart labels, making disposable, thin-form-factor solutions economically feasible at high volumes. InPlay also offers preprogramming services for the IN120, streamlining the manufacturing workflow and dramatically cutting production setup times, further amplifying operational efficiency for manufacturers. The IN120 is poised to transform smart label applications by significantly lowering barriers related to cost, complexity, and production speed, making active smart labels as economically viable as passive RFID labels, but with vastly superior functionality. The IN120 SoC will be available for sampling starting Q1'2026, with mass production planned shortly thereafter. InPlay Inc. is a pioneering technology company specializing in the development of advanced wireless communication solutions for the IIoT market. Our products are designed to deliver high performance, ultra-low power consumption, and robust security, addressing the most demanding requirements of industrial and consumer applications.
